Species differences in pharmacokinetics and drug teratogenesis.
about
Developmental toxicology of industrial alcohols: a summary of 13 alcohols administered by inhalation to ratsMethods to identify and characterize developmental neurotoxicity for human health risk assessment. III: pharmacokinetic and pharmacodynamic considerations.The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.Reference compounds for alternative test methods to indicate developmental neurotoxicity (DNT) potential of chemicals: example lists and criteria for their selection and use.A swine model of acute thrombocytopenia with prolonged bleeding time produced by busulfan.Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats.Corticosteroid use and risk of orofacial clefts.Reproductive and developmental toxicity of the components of gasolineVoluntary exercise together with oral caffeine markedly stimulates UVB light-induced apoptosis and decreases tissue fat in SKH-1 mice.Evaluation of developmental toxicants and signaling pathways in a functional test based on the migration of human neural crest cellsRetinoic acid induces Sertoli cell paracrine signals for spermatogonia differentiation but cell autonomously drives spermatocyte meiosis.Milk transfer and toxicokinetics of valproic Acid in lactating cynomolgus monkeys.Placenta transfer and toxicokinetics of valproic Acid in pregnant cynomolgus monkeys.Drug transporters in the human blood-placental barrier.Image analysis of Ca2+ signals as a basis for neurotoxicity assays: promises and challenges.Valproic acid for the treatment of hemorrhagic shock: a dose-optimization studyGuidance on classification for reproductive toxicity under the globally harmonized system of classification and labelling of chemicals (GHS).Potential human developmental toxicants and the role of animal testing in their identification and characterization.Embryonic stem cells and the next generation of developmental toxicity testing.In vitro acute and developmental neurotoxicity screening: an overview of cellular platforms and high-throughput technical possibilities.Prenatal exposure to environmental factors and congenital limb defects.The consequences of prenatal substance use for the developing fetus, newborn, and young child.sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain.The pharmacokinetics of phenylethyl alcohol (PEA): safety evaluation comparisons in rats, rabbits, and humans.Oral and dermal developmental toxicity studies of phenylethyl alcohol in rats.Developmental toxicity of indium in cultured rat embryos.Estimation of neonatal exposure after accidental ingestion of lufenuron in a breastfeeding mother.The high sensitivity of the rabbit to the teratogenic effects of 13-cis-retinoic acid (isotretinoin) is a consequence of prolonged exposure of the embryo to 13-cis-retinoic acid and 13-cis-4-oxo-retinoic acid, and not of isomerization to all-trans-rRetinoic Acid Receptor Signaling in Post-Natal Male Germ Cell Differentiation
P2860
Q23910245-ED1343B8-6716-4D27-AB49-BF0E82AA6EA1Q24814147-BA873C28-8094-4C5A-BAFE-EDF017B6ADB2Q30490602-6BAB840A-51BC-4907-A504-B1D0787564E1Q30835700-4F908138-692E-4B2D-BC6F-AACE5ABF21CFQ33433352-069CF646-6186-4B5A-A91D-EC779EEA7062Q33700983-CD370CCC-F19B-4879-B379-21E1F3764A86Q34819115-22E4BE49-2611-455B-9563-EDBFCE244072Q34849695-78883E60-22E9-4ED5-ABC3-056F3CC7360DQ35921745-84C3982D-4D54-4C3F-B993-AFA1E199E708Q36229064-9D2DD1D2-E1D6-4395-9BF2-9DEF56D27AB5Q36339894-652C47C0-CB3F-4CC9-9A54-0FACE14101B7Q37326490-A60715EC-C0F2-44DE-BDBD-70A511C6AFABQ37326643-EB4976E3-CBFE-4953-A5A8-757B4B7D5A97Q37395889-A006FAF2-E469-4530-A8BD-8B59E2253EECQ37531157-EAE7014D-9B56-4009-93B1-0A15C0CE0320Q37678405-5C63C7EF-F6B1-4395-9913-44D39F777755Q38165989-E6ADDB5B-F099-4CF1-8870-6DEA5B640EA0Q38625359-A0A09C11-2C8D-447F-9D78-4870926AF67CQ38698182-8C31025B-56FD-4BF6-9AED-C31638CC0EB7Q38753758-350E9E4D-8019-4B5E-819D-0911CDDE1B04Q38987429-AD7EE972-2F34-4FB5-9ABB-D3B051FA23EEQ40385860-4A84E70D-B18D-4BA9-A598-9604126DDDCFQ47360266-05D2478C-ABBB-4751-95F6-34F670113324Q50761012-5313C41F-BD1D-471C-BCA0-E42A52DA8629Q50761013-8090B52C-7F1A-492C-AC53-50C23606081EQ52176295-5F6DB87A-9CAD-4D4C-84EF-9D86FCF57CE3Q52585355-5941745C-1BDB-46EA-AC90-E46027AC1756Q53019029-6C8081BF-69F3-4432-B7C7-5B4287B3D3E1Q58340454-C4634BB3-968A-4CCE-AD8B-F440E54D00E4
P2860
Species differences in pharmacokinetics and drug teratogenesis.
description
1986 nî lūn-bûn
@nan
1986 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Species differences in pharmacokinetics and drug teratogenesis.
@ast
Species differences in pharmacokinetics and drug teratogenesis.
@en
Species differences in pharmacokinetics and drug teratogenesis.
@nl
type
label
Species differences in pharmacokinetics and drug teratogenesis.
@ast
Species differences in pharmacokinetics and drug teratogenesis.
@en
Species differences in pharmacokinetics and drug teratogenesis.
@nl
prefLabel
Species differences in pharmacokinetics and drug teratogenesis.
@ast
Species differences in pharmacokinetics and drug teratogenesis.
@en
Species differences in pharmacokinetics and drug teratogenesis.
@nl
P2860
P356
P1476
Species differences in pharmacokinetics and drug teratogenesis.
@en
P2093
P2860
P304
P356
10.1289/EHP.8670113
P577
1986-12-01T00:00:00Z